국민건강보험 12년 표본코호트자료에 근거한 국내 프로톤펌프저해제 사용 현황

Proton Pump Inhibitors’ Use in Korea Based on the National Health Insurance Sample Cohort Database (2002-2013)

This study was conducted to identify the overall PPI usage from 2002 to 2013 (12 years) in real world settings using the sample cohort data from the National Health Insurance Service. The number of PPI users increased by about 10.6 times over 12 years and the average annual growth rate was 26.5%. Annual PPI drug expenditure increased by 16.8 times during the period, with an average annual growth rate of 31.6%. PPI products mainly were prescribed in clinics, as primary medical institutions, accounting for 65% of overall prescriptions. Rabeprazole was the most frequently prescribed ingredient among the seven PPIs available in Korea, accounting for about 51% of all PPI users. Although rabeprazole accounted for more than half of the prescriptions in clinic (rabeprazole 55.5%, esomeprazole 21.0%), it was used at similar levels to esomeprazole in general hospitals (rabeprazole 31.1%, esomeprazole 29.8%). Taking into account rapid increase of PPI usage over 12 years, it is necessary to further discussion to establish strategy for safe use of PPI.